Bristol-Myers Squibb Compnay

Gilles Bouthillier

Jennifer X Qiao

Tammy C Wang

Jacques Y Roberge

Jacques Banville

Charles G Clark

Patrick Y S Lam

Rejean Ruel

Timur Gungor

Timothy F Herpin

Roger Remillard

Carl Thibeault

Hannguang J Chao

Robert P Rehfuss

Alexandre L'Heureux

Huji Tuerdi

Dora M Schnur

Yalei Liu

R Michael Lawrence

B Narasimhulu Naidu

Alain Martel

Michael A Walker

Neelakantan Balasubramanian

Michael R Lawrence

Patrick YS Lam

Timothy Herpin

Jacques Yves Roberge

Alexandre L L'HEUREUX

The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

[object Object]

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV 

Bicyclic heterocycles as HIV integrase inhibitors

Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formulawherein X, Z, X, R, R, R, R, R, Rand Y are as defined in the specification.

Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors

Growing community of inventors

Mercier, Canada

Gilles Bouthillier